Sexual health

From HPV to Cervical Cancer, Step by Step

Save

Most HPV infections never come close to becoming cancer. This piece walks through the actual pathway step by step — infection, clearance or persistence, precancerous cell changes, and the slow final step to invasive cancer — and explains how Pap and HPV co-testing catch it along the way, plus what an abnormal result does and doesn't mean.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

How does HPV actually turn into cervical cancer?

Cervical cancer almost never happens quickly or without warning. It develops through a slow, multi-step pathway that starts with a persistent high-risk HPV infection, moves through detectable precancerous cell changes, and only becomes cancer after years — often a decade or more — if nothing interrupts it along the way 1.

That slow timeline is part of the answer to does hpv cause cancer: yes, but only when a high-risk infection persists long enough to move through this pathway uninterrupted, which is also why the timeline itself is the reason cervical cancer is one of the more preventable cancers — there is a long window where screening can catch the pathway partway through.

Step one: infection, and why most of them go nowhere

The pathway begins with exposure to a high-risk HPV type, most commonly type 16 or 18, out of the roughly 40 hpv types that can infect the genital area. Most people who are exposed clear the infection within one to two years without it ever progressing, which means the vast majority of HPV infections never reach the next step of this pathway at all 1.

Clearing an infection is the normal outcome, not a lucky exception. Age, immune function, and how the body responds to the specific viral type all play a role in hpv clearance, and there is no reliable way to predict clearance for a given individual in advance.

Step two: persistence and precancerous cell changes

When a high-risk infection does not clear, the virus can begin altering the way cervical cells grow and divide. Over one to several years, this can produce precancerous cell changes — abnormal cells that are not cancer but are the tissue-level sign that the pathway has moved past simple infection 1.

Precancerous cell changes are not cancer, and most never become cancer, especially when they are found and monitored. This is the stage cervical screening is specifically designed to detect, catching tissue changes early enough that they can be monitored or treated well before they would ever become invasive cancer. Whether can you get rid of hpv once persistence has set in is a common question, and there is no simple answer — there is no treatment that clears the virus itself; care at this stage targets the precancerous cells it has caused, not the virus.

Step three: from precancer to invasive cancer, and why the timeline is so long

Left unmonitored and untreated, some precancerous changes continue to progress, eventually becoming invasive cervical cancer — cancer that has grown beyond the surface layer of cervical tissue. This final step typically takes additional years on top of the time already spent in the precancerous stage 1.

HPV causes roughly 39,300 cancers in the United States every year, and cervical cancer is the most common of them in women 2. This same persistence-to-cancer pathway plays out at other sites too — the hpv cancers beyond the cervix, including hpv throat cancer and anal cancer, follow a similar arc of persistent infection leading to precancerous change leading to cancer, just at a different location in the body 2. That long runway is precisely why regular screening, not a one-time test, is the strategy for cervical cancer: it gives repeated chances to catch the pathway during the precancerous stage, when treatment is simpler and outcomes are excellent.

How screening catches the pathway before cancer develops

Cervical screening looks for two different things that map onto this pathway: an HPV test checks for the high-risk viral infection itself, while a Pap test looks at the cervical cells directly for the precancerous changes an infection may have already caused. Used together, they catch the pathway at two different points 1.

A positive HPV test without abnormal cells on a Pap test generally means the infection is present but has not yet caused detectable changes — the earliest point on the pathway screening can see. An abnormal Pap result, with or without a positive HPV test, generally prompts closer follow-up to see how far along the pathway those cell changes have progressed. There is no equivalent routine test in the context of hpv testing in men, since there is no approved screening test that checks for HPV-related cell changes at other body sites the way cervical screening does for the cervix.

Why an abnormal result doesn't mean cancer

An abnormal cervical screening result is common and, on its own, does not mean cancer — it usually means further evaluation is needed to see exactly where on this pathway the cell changes sit. Most abnormal results reflect early, low-grade changes that often resolve on their own without ever needing treatment.

Screening decisions after an abnormal result work best through a shared decision-making process: seeking someone's participation, helping them compare options, weighing what matters most to them, and reaching a decision together, rather than a single directive from a clinician 3. That is also where overdiagnosis becomes a real, if uncomfortable, consideration in cancer screening generally: detecting something through screening that would never have gone on to cause symptoms or death is itself a harm, since it can lead to treatment that was never actually necessary 4.

Preventing the pathway from ever starting

The HPV vaccine works earlier in this pathway than any screening test can — it prevents the initial infection from a covered high-risk type, rather than catching cell changes after infection has already happened. Current guidance recommends routine vaccination at ages 11 to 12, catch-up vaccination through age 26, and a shared decision-making conversation for adults 27 to 45 5.

Condoms reduce, though do not eliminate, HPV transmission, since the virus spreads through skin-to-skin contact a condom does not fully cover 6. Vaccination, screening, and — for those already exposed — monitoring together form a layered defense against this pathway, each one covering a gap the others leave open.

Common questions

Typically a decade or more, and often longer. The pathway moves from initial infection through persistence, then precancerous cell changes, and only then to invasive cancer — a slow, multi-step process that gives regular screening many chances to catch it before cancer ever develops.

No. A positive high-risk HPV test means the virus is present, which is the first step of a pathway that most infections never complete. Most high-risk infections clear on their own before ever causing precancerous cell changes, let alone cancer.

It is uncommon. The vast majority of cervical cancer cases are linked to a persistent high-risk HPV infection, which is why HPV is described as a necessary step in nearly all cases, rather than one risk factor among several equally likely causes.

No. An abnormal Pap result usually means cell changes were found that need closer evaluation, most of which are early or low-grade and often resolve without treatment. Very few abnormal results turn out to be cancer at the time they are found.

No. The vaccine prevents infection from the HPV types it covers; it does not treat or clear an infection that is already present. This is why vaccination works best when given before any exposure to HPV, ideally in adolescence, well before the pathway described above ever has a chance to begin.

No. Many precancerous changes are found on screening, monitored, and either resolve on their own or are treated well before they would ever progress. Finding one is a reason for follow-up and monitoring, not a guarantee that cancer is coming.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When to seek care in this pathway

  • —Vaginal bleeding between periods, after sex, or after menopause
  • —Unusual, persistent vaginal discharge with a foul odor
  • —Pelvic pain that is new and does not resolve
  • —Unexplained weight loss alongside any of the above

This explains the general biological pathway from HPV infection to cervical cancer; it is educational information, not a diagnosis. Screening results and any follow-up care should be interpreted by a clinician familiar with an individual's full history.

References

  1. 1.Centers for Disease Control and Prevention (2024). Human Papillomavirus (HPV). CDC (cdc.gov/hpv). linkGeneral overview supporting that HPV is the most common STI, that most infections clear on their own, and that persistent high-risk-type infection can progress through precancerous cell changes to cancer; basis for describing the infection, clearance, and screening steps of the pathway.
  2. 2.Centers for Disease Control and Prevention (2024). Basic Information about HPV and Cancer. CDC (cdc.gov/cancer). linkSupports that HPV causes most cervical cancers plus some vaginal, vulvar, penile, anal, and oropharyngeal cancers, and that HPV causes roughly 39,300 cancers per year in the U.S., with cervical cancer the most common HPV-associated cancer in women.
  3. 3.Agency for Healthcare Research and Quality (2020). The SHARE Approach. Agency for Healthcare Research and Quality (AHRQ). link ✓Supports the five named steps of the SHARE Approach to shared decision making — seeking the patient's participation, helping them compare options, assessing values and preferences, reaching a decision together, and evaluating the decision — used here for decisions following an abnormal cervical screening result.
  4. 4.Welch HG, Black WC (2010). Overdiagnosis in cancer. Journal of the National Cancer Institute. doi:10.1093/jnci/djq099 ✓Supports the definition of cancer-screening overdiagnosis — detecting through screening a cancer that would never have caused symptoms or death — and that it represents a harm of screening because it leads to unnecessary treatment.
  5. 5.Centers for Disease Control and Prevention (Advisory Committee on Immunization Practices) (2024). ACIP Recommendations: Human Papillomavirus (HPV) Vaccine. CDC ACIP Recommendations. linkSupports the U.S. HPV vaccination recommendation: routine vaccination at ages 11-12, catch-up vaccination through age 26, and shared clinical decision-making for some adults ages 27-45.
  6. 6.Centers for Disease Control and Prevention (2024). Condom Use: An Overview. CDC (cdc.gov/condom-use). linkSupports that condoms provide only partial protection against STIs spread by skin-to-skin contact, such as HPV, since they only cover the area they cover.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library